HBV, page-5

I must stress that I am not convinced by this report but it is interesting that the last scientific presentation was on HBV and wasting money on new HBV research would seem pointless unless something was going on in the background. A quick review of the data provided in the presentation did provide some evidence that the new delivery approach could be attractive, albeit that there is a long way to go to get FDA approval for a trial. Make of this what you will.